Tokyo Tape
Sign in
← Nipro

Quarterly report · Q3

8086.TEDINET S100STZ2
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥439.1bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥545.2bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥406.3bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥22.4bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥13.2bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥20.0bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥15.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥13.8bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥22.1bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥14.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥12.6bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.0bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥13.5bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥8.1bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥1.11Tat 2023-12-31Cons.Assets
Total assets¥1.03Tat 2023-03-31Cons.Assets
Total assets¥1.05Tat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥831.3bnat 2023-12-31Cons.Liabilities
Total liabilities¥785.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥280.6bnat 2023-12-31Cons.Net assets
Net assets / equity¥242.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥240.2bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥79.4bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥89.7bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥77.442023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥16.552023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.052022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥42.692022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.352022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥68.612023-04-01 → 2023-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥24.852022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥37.822022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio21.9%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio20.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio21.3%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-12-31¥3.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-12-31¥642m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-12-31¥3.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-12-31−¥200m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥54.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥54.6bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥19.8bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue2023-04-01 → 2023-12-31¥345.3bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2023-04-01 → 2023-12-31¥340.3bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥5.0bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2023-04-01 → 2023-12-31¥35.4bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue2023-04-01 → 2023-12-31¥96.0bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue external2023-04-01 → 2023-12-31¥54.2bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥41.8bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentsegment profit2023-04-01 → 2023-12-31¥5.3bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue2023-04-01 → 2023-12-31¥48.6bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue external2023-04-01 → 2023-12-31¥43.9bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥4.7bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentsegment profit2023-04-01 → 2023-12-31¥1.6bn
—segment totalrevenue2023-04-01 → 2023-12-31¥490.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥438.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥51.5bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥42.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥493.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥439.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥54.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥42.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥3.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥530m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥2.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31¥166m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥28.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥28.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥22.5bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-12-31¥318.8bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-12-31¥314.2bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4.6bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-12-31¥30.8bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-12-31¥70.3bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-12-31¥53.6bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥16.8bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.2bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-12-31¥42.6bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-12-31¥38.0bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4.6bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.5bn
—segment totalrevenue2022-04-01 → 2022-12-31¥431.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥405.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥25.9bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥35.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥434.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥406.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥28.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥35.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 445
ItemContextValueUnit
Other clCurrentQuarterInstant34537000000JPY
Current liabilitiesPrior1YearInstant302910000000JPY
Current liabilitiesCurrentQuarterInstant358461000000JPY
Bonds payablePrior1YearInstant76700000000JPY
Bonds payableCurrentQuarterInstant85700000000JPY
Convertible bond type bonds with subscription rights to sharesPrior1YearInstant30210000000JPY
Convertible bond type bonds with subscription rights to sharesCurrentQuarterInstant30165000000JPY
Long term loans payablePrior1YearInstant316555000000JPY
Long term loans payableCurrentQuarterInstant298384000000JPY
Lease obligations nclPrior1YearInstant25265000000JPY
Lease obligations nclCurrentQuarterInstant24240000000JPY
Deferred tax liabilitiesPrior1YearInstant1276000000JPY
Deferred tax liabilitiesCurrentQuarterInstant1735000000JPY
Net defined benefit liabilityPrior1YearInstant5164000000JPY
Net defined benefit liabilityCurrentQuarterInstant5967000000JPY
Provision for directors retirement benefitsPrior1YearInstant686000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant531000000JPY
Provision for share based remuneration for directors and other officers nclPrior1YearInstant11000000JPY
Provision for share based remuneration for directors and other officers nclCurrentQuarterInstant10000000JPY
Provision for loss on litigation nclPrior1YearInstant153000000JPY
Provision for loss on litigation nclCurrentQuarterInstant204000000JPY
Other nclPrior1YearInstant26291000000JPY
Other nclCurrentQuarterInstant25867000000JPY
Noncurrent liabilitiesPrior1YearInstant482315000000JPY
Noncurrent liabilitiesCurrentQuarterInstant472809000000JPY
LiabilitiesPrior1YearInstant785225000000JPY
LiabilitiesCurrentQuarterInstant831270000000JPY
Capital stockPrior1YearInstant84397000000JPY
Capital stockCurrentQuarterInstant84397000000JPY
Capital surplusPrior1YearInstant－JPY
Capital surplusCurrentQuarterInstant1000000JPY
Retained earningsPrior1YearInstant95521000000JPY
Retained earningsCurrentQuarterInstant105026000000JPY
Treasury stockPrior1YearInstant-10748000000JPY
Treasury stockCurrentQuarterInstant-10749000000JPY
Shareholders equityPrior1YearInstant169170000000JPY
Shareholders equityCurrentQuarterInstant178677000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant7162000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant6471000000JPY
Deferred gains or losses on hedgesPrior1YearInstant-47000000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-53000000JPY
Foreign currency translation adjustmentPrior1YearInstant28716000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant57152000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1315000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1144000000JPY
Valuation and translation adjustmentsPrior1YearInstant37147000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant64714000000JPY
Non controlling interestsPrior1YearInstant35856000000JPY
Non controlling interestsCurrentQuarterInstant37237000000JPY
Net assetsPrior1YearInstant242173000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass